Gilead Receives FDA Approval to Extend Vemlidy Label for Pediatric Hepatitis B Treatment

Thursday, 28 March 2024, 15:04

Gilead Sciences has recently received approval from the U.S. FDA to expand the use of Vemlidy, their hepatitis B drug, to children as young as six years old. This extension offers new treatment options for pediatric patients with hepatitis B, potentially improving outcomes and quality of life for affected children.

https://store.livarava.com/05619f5d-ed15-11ee-8904-87cc5c87fb08.jpg — Gilead Receives FDA Approval to Extend Vemlidy Label for Pediatric Hepatitis B Treatment

Gilead Gains Label Extension for Hepatitis B Drug Vemlidy

The U.S. FDA has expanded the indication for Gilead's Vemlidy for children as young as six years old with hepatitis B virus.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.